MedTrace Logo

Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)

NCT00570882 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2014-09-25

No results posted yet for this study

Summary

This study is to evaluate the efficacy, safety, and feasibility of sunitinib in 4/2 and 2/1 regimen in previously untreated metastatic RCC to select the most promising regimen, which should be used in further studies of this patient population.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Sunitinib 2/1

Sunitinib 50 mg PO 2 weeks followed by 1 week rest

DRUG

Sunitinib 4/2

Sunitinib 50 mg PO 4 weeks followed by 2 week rest

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Jae-Lyun Lee, MD, PhD · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00570882 on ClinicalTrials.gov